Fiche traitement
carboplatin
Merck Sharp & Dohme LLC • Cancer, Parkinson
Suivi actif
Phase 3
Résumé
carboplatin est développé par Merck Sharp & Dohme LLC. Le traitement est actuellement en Phase 3. Il est associé à Cancer, Parkinson. Son objectif thérapeutique principal est À vérifier. Le statut actuel est : suivi actif.
À vérifier
À vérifier
Phase 3
Merck Sharp & Dohme LLC
United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, …
This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79b positive cancer cells in a targeted way and delivers vedotin to kill them. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with immunotherapy may kill more cancer cells in patients with diffuse large B-cell lymphoma.
2026-09-09
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Phase 3
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
À vérifier
Confiance automatique : 0%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT04665765, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Contrôle de cohérence : 85/100
L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.
Transparence et qualité de la fiche
données vérifiablesClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-09-09
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeRecrutement en cours
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréePhase 3
Études associées2
Publications associées18
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
25 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2021-01-18 | Début de l’étudeNCT04665765 | Registre d’essai clinique |
| 2025-11-21 | Début de l’étudeNCT06890338 | Registre d’essai clinique |
| 2026-07-10 | PublicationSevere Inflammatory Cystitis and Ureteritis Following Neoadjuvant TCHP (Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab) Therapy in HER2-Positive Breast Cancer: A Case Report and Literature Review. | Cureus |
| 2026-07-10 | PublicationConsolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). | JAMA oncology |
| 2026-07-12 | PublicationIntermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society |
| 2026-07-12 | PublicationAcute Appendicitis at Stem Cell Infusion During Autologous Transplantation for HIV-Associated Diffuse Large B-cell Lymphoma: A Case Report. | Cureus |
| 2026-07-14 | PublicationEfficacy of poloxamer Р188 in restoring the metabolic profile in myelosuppression: a non-invasive nuclear magnetic resonance spectroscopy study. | Biomeditsinskaia khimiia |
| 2026-07-14 | PublicationBevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer. | JAMA network open |
| 2026-07-14 | PublicationPrimary Small Cell Neuroendocrine Carcinoma of the Breast in a 75-Year-Old Woman With Aggressive Recurrence Despite Multimodal Therapy: A Case Report and Literature Review. | The American journal of case reports |
| 2026-07-15 | PublicationPerformance status 2 or higher in EMA labels for advanced non-small-cell lung cancer: a cross-sectional SmPC analysis. | Cancer treatment and research communications |
| 2026-07-15 | PublicationIntegrated Network Pharmacology and Proteomics Reveal Anti-tumor Mechanism of Securinine in Ovarian Cancer. | Chinese journal of integrative medicine |
| 2026-07-22 | PublicationAn evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal. | Expert review of anticancer therapy |
| 2026-07-22 | PublicationExploding retinoblastoma- Management of spontaneous scleral rupture in an infant with bilateral retinoblastoma. | Retinal cases & brief reports |
| 2026-08-08 | PublicationDrug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM? | Future science OA |
| 2026-08-08 | PublicationDUSP5 contributes to platinum resistance in ovarian cancer: single-cell discovery and functional validation. | Frontiers in pharmacology |
| 2026-08-13 | PublicationRepurposing Alzheimer's and ovarian cancer drugs as sonosensitizers for glioblastoma via a positive-unlabeled learning and 3D bioprinting-based new approach methodology (NAM). | PloS one |
| 2026-08-13 | PublicationSequential development of isolated ACTH deficiency and fulminant type 1 diabetes as delayed immune-related endocrine adverse events. | BMJ case reports |
| 2026-08-16 | Création de l’enregistrementNCT06890338 | Registre d’essai clinique |
| 2026-08-16 | PublicationEvaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids. | Cancer biology & therapy |
| 2026-08-16 | PublicationA mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma. | Oncoimmunology |
| 2026-08-16 | PublicationLeverage of quick-soluble gelatin microparticles in transarterial chemoembolization of canine urothelial carcinomas. | The veterinary quarterly |
| 2026-09-09 | Dernière mise à jour des donnéescarboplatin | Biomedical Watch |
| 2026-09-14 | Création de l’enregistrementNCT04665765 | Registre d’essai clinique |
| 2027-06-28 | Fin de l’étude prévue / enregistréeNCT04665765 | Registre d’essai clinique |
| 2030-02-01 | Fin de l’étude prévue / enregistréeNCT06890338 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
2 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT04665765 | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | ACTIVE_NOT_RECRUITING | United States | City of Hope Medical Center |
| NCT06890338 | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Phase 2 | RECRUITING | United States | AbbVie |
Publications liées
18 publication(s)Publications liées
18 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids. Voir source | 41520277 | 10.1080/15384047.2025.2611602 | Cancer biology & therapy | |
| A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma. Voir source | 41732954 | 10.1080/2162402X.2026.2631244 | Oncoimmunology | |
| Leverage of quick-soluble gelatin microparticles in transarterial chemoembolization of canine urothelial carcinomas. Voir source | 42216429 | 10.1080/01652176.2026.2679557 | The veterinary quarterly | |
| Repurposing Alzheimer's and ovarian cancer drugs as sonosensitizers for glioblastoma via a positive-unlabeled learning and 3D bioprinting-based new approach methodology (NAM). Voir source | 42585241 | 10.1371/journal.pone.0354981 | PloS one | |
| Sequential development of isolated ACTH deficiency and fulminant type 1 diabetes as delayed immune-related endocrine adverse events. Voir source | 42586593 | 10.1136/bcr-2026-274439 | BMJ case reports | |
| Drug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM? Voir source | 42559863 | 10.1080/20565623.2026.2712209 | Future science OA | |
| DUSP5 contributes to platinum resistance in ovarian cancer: single-cell discovery and functional validation. Voir source | 42564493 | 10.3389/fphar.2026.1842271 | Frontiers in pharmacology | |
| An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal. Voir source | 42483956 | 10.1080/14737140.2026.2708761 | Expert review of anticancer therapy | |
| Exploding retinoblastoma- Management of spontaneous scleral rupture in an infant with bilateral retinoblastoma. Voir source | 42484521 | 10.1097/ICB.0000000000001963 | Retinal cases & brief reports | |
| Performance status 2 or higher in EMA labels for advanced non-small-cell lung cancer: a cross-sectional SmPC analysis. Voir source | 42447750 | 10.1016/j.ctarc.2026.101313 | Cancer treatment and research communications | |
| Integrated Network Pharmacology and Proteomics Reveal Anti-tumor Mechanism of Securinine in Ovarian Cancer. Voir source | 42448946 | 10.1007/s11655-026-4246-1 | Chinese journal of integrative medicine | |
| Efficacy of poloxamer Р188 in restoring the metabolic profile in myelosuppression: a non-invasive nuclear magnetic resonance spectroscopy study. Voir source | 42446256 | 10.18097/PBMCR1662 | Biomeditsinskaia khimiia | |
| Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer. Voir source | 42446878 | 10.1001/jamanetworkopen.2026.23166 | JAMA network open | |
| Primary Small Cell Neuroendocrine Carcinoma of the Breast in a 75-Year-Old Woman With Aggressive Recurrence Despite Multimodal Therapy: A Case Report and Literature Review. Voir source | 42444104 | 10.12659/AJCR.952443 | The American journal of case reports | |
| Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial. Voir source | 42435644 | 10.1016/j.ijgc.2026.104816 | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | |
| Acute Appendicitis at Stem Cell Infusion During Autologous Transplantation for HIV-Associated Diffuse Large B-cell Lymphoma: A Case Report. Voir source | 42437228 | 10.7759/cureus.110505 | Cureus | |
| Severe Inflammatory Cystitis and Ureteritis Following Neoadjuvant TCHP (Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab) Therapy in HER2-Positive Breast Cancer: A Case Report and Literature Review. Voir source | 42422612 | 10.7759/cureus.110454 | Cureus | |
| Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). Voir source | 42424047 | 10.1001/jamaoncol.2026.2330 | JAMA oncology |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-09-09
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.